Genic Co (123330) Fair Value & Analysis
Consumer Defensive · KR · Market cap 189B KRW
Fair value as of: Jul 22, 2026
From 22 valuation models · updated 19 days ago
Share price +14.1% over the past month.
A strong business, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- Our model range runs from 21,639 KRW (bear) to 36,066 KRW (bull), base 28,853 KRW. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 78/100 (high quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
60‑month range 3,060 KRW – 42,600 KRW · fair‑value band 21,639 KRW – 36,066 KRW · the 29,600 KRW price screens above the 28,853 KRW fair value. Dashed = 300-day average. As of Jul 22, 2026.
Analysis
Genic Co (123330) currently trades at 29,600 KRW, while our model-based Fair Value estimate is 28,853 KRW, implying the stock looks roughly 2.5% fairly valued today. The Quality Score stands at 78/100 (high quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Genic Co generated revenue of 89.7B KRW at a net margin of 21.0%. Revenue grew 64.7% year over year. It earns a return on equity of 53.7%. Net debt stands at 3.7B KRW. Fundamentals as of Jul 22, 2026
Our scenario range runs from 21,639 KRW (bear case) to 36,066 KRW (bull case); at 29,600 KRW, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 33% below its 52-week high and 90% above its 52-week low, currently above its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at -26% fair-value upside, at -3%, 123330 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 22 models by family
Widest divergence: Growth Earnings (38,937 KRW) versus Asset-Based (3,515 KRW). Highest evidence: Growth DCF (80).
Notify me when 123330 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 79 · Market factors (momentum, volatility) 46
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Genic Co., Ltd. researches, develops, manufactures, and sells cosmetics and pharmaceuticals in South Korea and internationally.
Full company description
Genic Co., Ltd. researches, develops, manufactures, and sells cosmetics and pharmaceuticals in South Korea and internationally. The company provides hydrogel masks, sheet masks, cream wrapping masks, mud masks, and bio cellulose masks; nose patch, eye patch, body patch, eye gel, lifting patch, and outdoor patches; cleanser, toner, lotion, serum, cream, sunscreen, and cleansing/soothing/oil pad; and shampoo and tonic. It offers its products under the CELEDERMA, CELEDERMA daily, and Excuse my Frank brands. Genic Co., Ltd. was founded in 2001 and is headquartered in Seongnam-si, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Genic Co reported revenue of 78.2B KRW in FY2025 versus 38.4B KRW in FY2021, a compound +19.5%/yr. Reported net income was 18.9B KRW in FY2025.
Watch 123330: get an alert when its fair value changes →
Peer Group
Household & Personal Products · 244 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Household & Personal Products median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Household & Personal Products stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| The Procter & Gamble Company PG | $146.80 | $108.16 | -26% |
| Unilever PLC ULN | 1,080 MXN | 1,273 MXN | +18% |
| Hindustan Unilever Limited HINDUNILVR | ₹2,144 | ₹1,000 | -53% |
| Essity AB ESSITYA | kr 279.00 | kr 250.02 | -10% |
| Godrej Consumer Products Limited GODREJCP | ₹1,088 | ₹367.64 | -66% |
| Marico Limited MARICO | ₹846.75 | ₹233.05 | -72% |
| APR Co 278470 | 375,000 KRW | 151,222 KRW | -60% |
| Dabur India Limited DABUR | ₹429.45 | ₹181.60 | -58% |
| Kimberly-Clark de México, S. A. B. de C. V., KIMBERA | 38.07 MXN | 50.09 MXN | +32% |
| PT Unilever Indonesia Tbk UNVR | 1,730 IDR | 1,934 IDR | +12% |
Compare Genic Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Frequently asked questions
Is Genic Co (123330) overvalued or undervalued?
What is the fair value of 123330?
What is the quality score of 123330?
What is the revenue of Genic Co (123330)?
What is the net profit margin of 123330?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Genic Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.